Stevens RM, et al. – Via performing a study involving patients aged 45–80 years who had stable knee osteoarthritis (OA), experts evaluated the efficiency and safety of high-purity synthetic trans-capsaicin (CNTX-4975) in patients with chronic moderate-to-severe OA–associated knee pain. Effectiveness was assessed in 172 patients. Greater reductions in the area under the curve for the pain score were noted with CNTX-4975 in the 0.5-mg and 1.0-mg groups vs the placebo group at week 12. In the 1.0-mg group, notable improvements were sustained at week 24. In the placebo and CNTX-4975 1.0-mg groups, treatment-emergent adverse events were similar. Hence, CNTX-4975 offered dose-dependent improvement in knee OA–associated pain. In OA knee pain through 24 weeks, CNTX-4975 1.0 mg produced a notable contraction and CNTX-4975 0.5 mg significantly improved pain at 12 weeks; however, the impact was not evident at 24 weeks.